Black checkmark with a sparkle and a curved line underneath on a white background.
Company

Azitra, Inc.

Ticker
AZTR
Sector
Industry
Report date
November 14, 2026
Valye AI Score

97

Very high visibility
Recent developments
Recent developments summary

Recent developments include expansion of ATR-04 clinical trial eligibility, pausing of the ATM program with ex vivo results announced for ATR-COSF, and implementation of a 1-for-10 reverse stock split. The company also completed a private placement to advance cosmetic protein and peptide programs and received NYSE American listing compliance notices.

Recent developments:
  • Azitra expanded eligibility criteria for the ATR-04 Phase 1/2 clinical trial in October 2026 [N1].
  • The company paused its ATM program and announced ex vivo results for ATR-COSF in October 2026 [N2].
  • Azitra announced and implemented a 1-for-10 reverse stock split in October 2026 [N3][N4].
  • Azitra completed a private placement to advance new cosmetic protein and peptide programs in March 2026 [N6].
  • The company received a NYSE American listing compliance notice in March 2026 and regained compliance in August 2026 [N7].
Overview

Azitra, Inc. develops genetically engineered bacterial therapies for dermatologic diseases, leveraging a proprietary microbial library and AI-driven drug discovery platform. The company focuses on engineering Staphylococcus epidermidis strains to deliver therapeutic proteins directly into the skin, bypassing the stratum corneum barrier. Its lead clinical programs target rare and chronic skin conditions such as Netherton syndrome (ATR-12) and EGFR inhibitor-associated rash (ATR-04). Azitra holds exclusive licenses for advanced genetic engineering technologies and collaborates with leading academic institutions to enhance its platform and pipeline. The company has not yet commenced commercial operations and is advancing multiple clinical trials while exploring strategic partnerships to broaden its precision dermatology portfolio.

Executive summary

Azitra, Inc. is an early-stage clinical biopharmaceutical company focused on precision dermatology therapies using engineered proteins and live biotherapeutic products derived from a proprietary microbial library. The company has advanced lead candidates ATR-12 and ATR-04 into clinical trials, with ATR-04 receiving FDA Fast Track designation. Recent developments include pausing the ATM program, expanding ATR-04 trial eligibility, and implementing a 1-for-10 reverse stock split. Financially, as of September 30, 2026, Azitra held $3.75 million in cash with a current ratio of 3.11 and reported a net loss of $2.95 million for the nine months ended September 30, 2026. Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.

Scenarios for AZTR

Bull case model:

Azitra's innovative approach to precision dermatology using genetically engineered commensal bacteria offers a novel therapeutic modality addressing unmet needs in skin diseases. The company's proprietary microbial library and AI-driven platform enable discovery of unique therapeutic proteins and peptides. Clinical progress with lead candidates ATR-12 and ATR-04, including FDA Fast Track designation for ATR-04, demonstrates advancement toward potential regulatory milestones. Strategic academic partnerships and exclusive technology licenses support platform expansion and pipeline diversification, positioning Azitra to build a sustainable portfolio of precision dermatology products.

Bear case model:

Azitra remains an early-stage clinical company with no commercial products or revenue, relying on successful clinical development and regulatory approvals for future viability. The company faces risks related to clinical trial outcomes, regulatory hurdles, and potential delays or discontinuations, as evidenced by the pause of the ATM program. Financially, Azitra reported net losses and limited cash reserves as of September 2026, with risks of dilution from outstanding warrants and options. Compliance with NYSE American listing standards remains uncertain, posing potential market and capital access challenges. The novel nature of live biotherapeutic products also entails scientific and manufacturing complexities that may impact development timelines and costs.

Moat:

Azitra's moat derives from its proprietary microbial library of over 1,500 unique bacterial strains, extensive strain diversity of S. epidermidis, and a platform augmented by AI and machine learning for drug discovery. The exclusive license to Fred Hutch's SyMPL genetic engineering technology expands the range of genetically tractable bacterial species, potentially enhancing product candidate development. The company's focus on genetically engineered live biotherapeutics for dermatology, combined with collaborations with premier academic institutions and a management team with deep biotech experience, creates barriers to entry and a differentiated position in precision dermatology therapeutics.

Risks overview
Risks summary
The most significant risks for Azitra relate to clinical development uncertainties, financial constraints, and regulatory compliance challenges that could materially affect its operational continuity and growth prospects.
Risks details:

• Clinical Development Risk: Azitra's lead programs are in early clinical stages with inherent risks of trial failure, delays, or adverse safety findings that could impede product development.
• Financial and Liquidity Risk: The company reported net losses and holds limited cash reserves, with potential dilution from outstanding warrants and options, which may affect its ability to fund operations and development.
• Regulatory and Compliance Risk: Azitra faces regulatory risks including maintaining FDA approvals and compliance with NYSE American listing standards, with potential delisting impacting liquidity and capital raising.
• Program Discontinuation Risk: The recent pause of the ATM program highlights risks that development programs may be halted due to scientific, clinical, or strategic reasons.
• Market and Commercialization Risk: Azitra has not commenced commercial operations and faces uncertainties in market acceptance, reimbursement, and competition in precision dermatology.

FINAL FORECAST FOR AZTR

Final take one line
Azitra, Inc. is a clinical-stage precision dermatology biotech with a proprietary microbial platform advancing genetically engineered live biotherapeutics through early clinical trials and facing typical early-stage development and financial risks.
Final take 12 to 24 month view

Business trends: Advancement of genetically engineered bacterial therapies for dermatologic diseases with clinical trials progressing for lead candidates ATR-12 and ATR-04, supported by AI-driven discovery and academic partnerships.
Execution milestones: Completion of Phase 1b/2a trials dosing, reporting of initial safety data, expansion of clinical trial eligibility, and strategic corporate actions including reverse stock split and private placements.
Key risks: Clinical trial uncertainties, financial constraints with limited cash and dilution risk, regulatory compliance challenges including NYSE listing standards, and potential program discontinuations impacting pipeline continuity.

Valye AI Visibility Research Score

Very high visibility

Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).

97
LLM visibility overview
LLM Visibility known facts
  • Azitra, Inc. is a Delaware corporation formed in 2014 focused on developing innovative therapies for precision dermatology using engineered proteins and topical live biotherapeutic products [S1].
  • The company has built a proprietary microbial library of approximately 1,500 unique bacterial strains, including over 900 unique strains of Staphylococcus epidermidis, which are screened for therapeutic characteristics [S1].
  • Azitra uses artificial intelligence and machine learning technology to analyze and predict drug-like molecules from its microbial library, collaborating with Carnegie Mellon University for genomic and peptidomic analysis [S1].
  • The company holds an exclusive worldwide license from Fred Hutchinson Cancer Center for SyMPL genetic engineering technology, enabling transformation of previously genetically intractable bacterial strains [S1].
  • Azitra's lead product candidates include ATR-12 for Netherton syndrome, ATR-04 for EGFR inhibitor-associated rash, and ATR-01 for ichthyosis vulgaris, all genetically engineered strains of S. epidermidis [S1].
  • ATR-12 Phase 1b/2a clinical trial commenced dosing in August 2024 with initial safety results reported in the first half of 2025 [S1].
  • ATR-04 received FDA IND clearance in August 2024 and Fast Track designation in September 2024; Phase 1/2 clinical trial dosing began in Q3 2025 [S1][N8].
  • Azitra has paused its ATM program and announced ex vivo results for ATR-COSF as of October 2026 [N2].
  • The company announced and implemented a 1-for-10 reverse stock split in October 2026 [N3][N4].
  • Azitra expanded eligibility criteria for the ATR-04 Phase 1/2 clinical trial in October 2026 [N1].
  • Azitra has partnerships with Carnegie Mellon University, Fred Hutchinson Cancer Center, Yale University, Duke University, and others to support its platform and pipeline development [S1].
  • As of September 30, 2026, Azitra had cash and cash equivalents of approximately $3.75 million and current assets of about $4.79 million, with current liabilities of $1.54 million, resulting in a current ratio of 3.11 and a cash ratio of 2.44 [S2].
  • The company reported a net loss of approximately $2.95 million for the nine months ended September 30, 2026, with basic and diluted EPS of -$0.29 [S2].
  • Azitra has not commenced commercial operations and reported zero revenue for the fiscal year ended December 31, 2025 [S1][S2].
  • The company received a NYSE American listing compliance notice in March 2026 and regained compliance in August 2026 but remains at risk of future noncompliance due to stockholders' equity below minimum requirements [N7][S2].
  • Outstanding warrants and options significantly exceed shares outstanding, posing potential dilution risks [S2].
  • Management includes CEO Francisco D. Salva and COO Dr. Travis Whitfill, with extensive biotech and venture capital experience [S1].
Sources
Sources - Context summary

Generated 2026-11-15

Sources - Earning calls
Sources - Other context
Sources - SEC Filings
  • S1 | 2026-02-27 | 10-K
  • S2 | 2026-11-12 | 10-Q
Sources - News headlines
  • N1 | 2026-10-29 | www.nasdaq.com | Azitra, Inc. Expands Eligibility for ATR-04 Phase 1/2 Clinical Trial | https://www.nasdaq.com/articles/azitra-inc-expands-eligibility-atr-04-phase-1-2-clinical-trial
  • N2 | 2026-10-26 | www.nasdaq.com | Azitra, Inc. Pauses ATM Program and Announces Ex Vivo Results for ATR-COSF | https://www.nasdaq.com/articles/azitra-inc-pauses-atm-program-and-announces-ex-vivo-results-atr-cosf
  • N3 | 2026-10-22 | www.nasdaq.com | Azitra, Inc. Announces 1-for-10 Reverse Stock Split | https://www.nasdaq.com/articles/azitra-inc-announces-1-10-reverse-stock-split
  • N4 | 2026-10-16 | www.nasdaq.com | Azitra To Implement 1-for-10 Reverse Stock Split | https://www.nasdaq.com/articles/azitra-implement-1-10-reverse-stock-split
  • N5 | 2026-06-23 | www.nasdaq.com | Top Biotech Gainers: TNON Files S-1, NVCT Inks License Deal, FTH On Watch, RGNX To Resubmit BLA | https://www.nasdaq.com/articles/top-biotech-gainers-tnon-files-s-1-nvct-inks-license-deal-fth-watch-rgnx-resubmit-bla
  • N6 | 2026-03-20 | www.nasdaq.com | Azitra Prices Private Placement To Advance New Cosmetic Protein & Peptide Programs; Stock Up | https://www.nasdaq.com/articles/azitra-prices-private-placement-advance-new-cosmetic-protein-peptide-programs-stock
  • N7 | 2026-03-16 | www.nasdaq.com | Azitra Gets NYSE American Listing Compliance Notice | https://www.nasdaq.com/articles/azitra-gets-nyse-american-listing-compliance-notice
  • N8 | 2024-09-18 | www.nasdaq.com | Azitra's ATR-04 Gets FDA Fast Track Designation For Skin Rash Linked To EGFR Inhibitors | https://www.nasdaq.com/articles/azitras-atr-04-gets-fda-fast-track-designation-skin-rash-linked-egfr-inhibitors
Important legal disclaimer

This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Blue logo with a stylized checkmark and star above the blue text 'VALYE' on a black background.

Generated by Valye SEC Pipeline Engine